2022 Annual Meeting | C99 - Neurologic Complications of Novel Anti-neoplastic Therapies Including Immunotherapy

Date Tuesday 04/05/22

Time 01:00 PM - 03:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Yazmin Odia, MD, MS, FAAN

Topic(s) Neuro-oncology

Learning Objectives Participants should become familiar with the distinct types of anti-neoplastic therapies, including cytotoxic, biologic, hormone, immunotherapy, radiation and other multimodal therapies, and their unique neurological complications, as well as understand the underlying mechanisms of actions, interpret clinical and radiographic manifestations, and manage the neurological toxicities relative to the distinct types of anti-neoplastic therapies.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM PDT	Introduction	Introduction to Course and Novel Cancer Therapies Yazmin Odia, MD, MS, FAAN
01:00 PM - 01:00 PM PDT	Speaker	Walk-in Slides Yazmin Odia, MD, MS, FAAN
01:05 PM - 01:40 PM PDT	Speaker	Complications of Cytotoxic, Biologic, and Hormone Therapies Ekokobe Fonkem, DO
01:40 PM - 02:15 PM PDT	Speaker	Complications of Immunotherapies Reena P. Thomas, MD, PhD
02:15 PM - 03:50 PM PDT	Speaker	Complications of Radiation and Multimodal Therapies Yazmin Odia, MD, MS, FAAN
03:50 PM - 04:00 PM PDT	Q&A	Panel Discussion Yazmin Odia, MD, MS, FAAN, Reena P. Thomas, MD, PhD, Ekokobe Fonkem, DO

Faculty Disclosures
Yazmin Odia, MD, MS, FAAN	Dr. Odia has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for PharPoint. Dr. Odia has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GammaTile.
Reena P. Thomas, MD, PhD	The institution of Dr. Thomas has received research support from NIH. The institution of Dr. Thomas has received research support from Health Resources & Services Administration. The institution of Dr. Thomas has received research support from California Institute of Regenerative Medicine. Dr. Thomas has received intellectual property interests from a discovery or technology relating to health care.
Ekokobe Fonkem, DO	Dr. Fonkem has received personal compensation for serving as an employee of Barrow Neurological Institute. Dr. Fonkem has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Fonkem has stock in Global Cancer Technology.